1305 Coformulation of favezelimab and pembrolizumab as neoadjuvant therapy for resectable cutaneous squamous cell carcinoma (cSCC): Results from cohort a of the phase 2 keyform-010 studyMatteo S Carlino, Bella Nguyen, Ann W. Silk et al.|Unknown|2025Cited by 0